Filing Flows

Filing Flows › Lexicon Pharmaceuticals (LXRX) › Next earnings date

Lexicon Pharmaceuticals (LXRX) earnings: beat the estimate

Lexicon Pharmaceuticals (LXRX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.03 against −$0.05 (+43.3%). Revenue was $11.2M for Q3 2026, -21% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+43.3% vs estimate
Beat rate80%

The last report

Lexicon Pharmaceuticals reported revenue of $11.2M for the third quarter 2026 (-21% Y/Y), net loss $14.0M. How it makes money → · Every quarter →

Lexicon Pharmaceuticals: EPS against the estimate, last 5 reportsLexicon Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.07−$0.04Nov 25−$0.07−$0.04Mar 26−$0.04$0.00May 26−$0.05−$0.06Aug 26−$0.05−$0.03Nov 26
Latest (Nov 26): Estimate −$0.05, Reported −$0.03.

Lexicon Pharmaceuticals' latest quarter

Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Lexicon Pharmaceuticals beat earnings?

Lexicon Pharmaceuticals (LXRX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.03 against −$0.05 (+43.3%).

When does LXRX report earnings?

The next date is not set yet.

Does Lexicon Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.